MS Clinical Trials in Colorado
36 active trials · 18 recruiting
36 active multiple sclerosis clinical trials have at least one study site in Colorado, 18 of them currently recruiting participants. Trials are listed from ClinicalTrials.gov and cover disease-modifying therapies, symptom treatments, rehabilitation and imaging studies.
Eligibility, contact details and the exact site address are on each trial's ClinicalTrials.gov record, linked from every trial page. MS Buddy also lists 9 MS treatment centers in Colorado; many trial sites are run from those centers, and your neurologist is the best first person to ask about joining a study.
Active MS trials with sites in Colorado
RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Sponsor: TG Therapeutics, Inc.
Ublituximab · Placebo
25 states800 participantsDetails ›
RecruitingPhase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Sponsor: Amgen
Ocrelizumab (US) · Ocrelizumab (EU)
17 states444 participantsDetails ›
RecruitingPhase 2
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Sponsor: Hoffmann-La Roche
Ocrelizumab Test Formulation · Ocrelizumab Reference Formulation
8 states182 participantsDetails ›
RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Sponsor: Celgene
BMS-986368 · Placebo
11 states200 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Teriflunomide
35 states1600 participantsDetails ›
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Sponsor: TG Therapeutics, Inc.
No Intervention
29 states500 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Placebo
38 states900 participantsDetails ›
RecruitingNA
Blood Flow Restriction And Veterans With MS
Sponsor: VA Office of Research and Development
Low-Load Exercise with Blood Flow Res… · Low-Load Exercise Control Group
1 state58 participantsDetails ›
Recruiting
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Sponsor: Kyverna Therapeutics
KYV-101
1 state70 participantsDetails ›
RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
CC-97540 · Fludarabine
14 states120 participantsDetails ›
RecruitingPhase 1
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Sponsor: AstraZeneca
AZD0120 - Regimen 1 · AZD0120 - Regimen 2
8 states24 participantsDetails ›
RecruitingPhase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Autologous Hematopoietic Stem Cell Tr… · Best Available Therapy (BAT)
15 states156 participantsDetails ›
Recruiting
Care in Multiple Sclerosis (MS)
Sponsor: NYU Langone Health
6 states386 participantsDetails ›
RecruitingPhase 4
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
Sponsor: University of Colorado, Denver
Ozanimod
3 states100 participantsDetails ›
Recruiting
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Sponsor: Biogen
Diroximel Fumarate · Avonex
2 states908 participantsDetails ›
RecruitingNA
Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery
Sponsor: University of Colorado, Denver
Closed Loop Trans-Auricular Vagus Ner… · Placebo
1 state70 participantsDetails ›
RecruitingNA
Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS
Sponsor: University of Colorado, Boulder
Transcutaneous electrical nerve stimu…
1 state60 participantsDetails ›
RecruitingPhase 4
Home Based Infusions for Ocrelizumab
Sponsor: University of Colorado, Denver
Ocrelizumab at home
1 state110 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
Sponsor: Hoffmann-La Roche
Ocrelizumab · Ocrelizumab
16 states769 participantsDetails ›
Closed to new patientsPhase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsor: Novartis Pharmaceuticals
Remibrutinib · Teriflunomide
23 states1011 participantsDetails ›
Closed to new patientsPhase 4
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
Sponsor: Novartis Pharmaceuticals
Ofatunumab
4 states24 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
Sponsor: Hoffmann-La Roche
Fenebrutinib · Ocrelizumab
24 states985 participantsDetails ›
Closed to new patientsPhase 3
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Sponsor: Novartis Pharmaceuticals
Ofatumumab approved dose · Ofatumumab new dose
24 states196 participantsDetails ›
Closed to new patientsPhase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsor: Novartis Pharmaceuticals
Remibrutinib · Teriflunomide
27 states1001 participantsDetails ›
Closed to new patientsPhase 3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Sponsor: Novartis Pharmaceuticals
Ofatumumab · Tetanus toxoid (TT) containing vaccin…
32 states1882 participantsDetails ›
Closed to new patientsPhase 2
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
Sponsor: Fred Hutchinson Cancer Center
Anti-Thymocyte Globulin · Autologous Hematopoietic Stem Cell Tr…
2 states53 participantsDetails ›
Closed to new patientsPhase 3
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Sponsor: TG Therapeutics, Inc.
Ublituximab
14 states1100 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Sponsor: Hoffmann-La Roche
Fenebrutinib · Teriflunomide
23 states746 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
Sponsor: Hoffmann-La Roche
Ocrelizumab · Ocrelizumab
20 states864 participantsDetails ›
Closed to new patientsPhase 3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Sponsor: Sanofi
Tolebrutinib · Placebo
27 states2500 participantsDetails ›
Closed to new patientsPhase 3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
Sponsor: Hoffmann-La Roche
Ocrelizumab
26 states1300 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
Sponsor: Hoffmann-La Roche
Ocrelizumab · Ocrelizumab Placebo
11 states188 participantsDetails ›
Closed to new patientsPhase 2
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
Sponsor: Hoffmann-La Roche
Ocrelizumab
5 states23 participantsDetails ›
Closed to new patients
Biobank For MS And Other Demyelinating Diseases
Sponsor: Accelerated Cure Project for Multiple Sclerosis
9 states3226 participantsDetails ›
Closed to new patients
Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis
Sponsor: The Cleveland Clinic
MRI
9 states420 participantsDetails ›
Closed to new patientsPhase 4
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
Sponsor: The Cleveland Clinic
Early Highly Effective Therapies Group · Escalation Therapies Group
8 states800 participantsDetails ›
